Axsome Therapeutics (AXSM) Operating Expenses (2015 - 2026)

Axsome Therapeutics' Operating Expenses history runs 12 years deep, the most recent figure standing at $254.6 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 42.65% year-over-year to $254.6 million; the TTM figure through Mar 2026 stood at $881.4 million (up 25.48% YoY), while the FY2025 annual figure was $805.3 million, up 20.86% from the prior year.
• Operating Expenses came in at $254.6 million for Q1 2026 at Axsome Therapeutics, up from $223.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $254.6 million in Q1 2026 to a low of $38.3 million in Q1 2022.
• A 5-year average of $144.6 million and a median of $165.2 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 163.65% in 2023 and advanced 12.71% in 2024, its largest moves.
• Axsome Therapeutics' Operating Expenses stood at $84.3 million in 2022, then surged by 101.45% to $169.8 million in 2023, then increased by 12.71% to $191.4 million in 2024, then gained by 16.5% to $223.0 million in 2025, then grew by 14.17% to $254.6 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $254.6 million, $223.0 million, and $217.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison